Axim Biotechnologies Inc (AXIM)

[Devolution]

Agreed, and to say it another way, if there was no Immunopass what-so-ever, buying at these prices just in consideration of the DED line would make sense.

The DED line has, on its own, the ability to be a (multi) billion dollar driver.

https://www.globenewswire.com/news-release/2021/08/03/2273798/33692/en/AXIM-Biotechnologies-to-Acquire-Technology-Including-Two-FDA-Cleared-510-k-s-for-Diagnostic-Testing-of-Dry-Eye-Disease.html



Even if the market cap of AXIM went to just 1 billion (not the "multi" billion dollar driver discussed in the interview from August 2021, above), the pps would be above $7 per share. That would be a 2,800% increase from today's prices - not a bad return in a single year.

Although my attention recently moved to the SPAC called NorthView Acquisition Corp., which has as one of its founders, Peter O'Rouke (who is currently on the AXIM Board of Directors), I still pick up a few shares of AXIM each day at close to the bottom of the market (today was 579 shares @ .22).

I did want to discuss my thoughts on NorthView here, but as this board is dedicated to AXIM, if you do have an interest in checking out NorthView, there is a board currently discussing it (NVAC, formerly known as NVACU before yesterday's Press Release - explained at length on that board).

Godspeed to all.